AR022510A1 - Formulaciones de vacunas contra el papilomavirus humano - Google Patents

Formulaciones de vacunas contra el papilomavirus humano

Info

Publication number
AR022510A1
AR022510A1 ARP000100495A ARP000100495A AR022510A1 AR 022510 A1 AR022510 A1 AR 022510A1 AR P000100495 A ARP000100495 A AR P000100495A AR P000100495 A ARP000100495 A AR P000100495A AR 022510 A1 AR022510 A1 AR 022510A1
Authority
AR
Argentina
Prior art keywords
formulations
against human
vaccines against
salt
human papilomavirus
Prior art date
Application number
ARP000100495A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR022510A1 publication Critical patent/AR022510A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Unas nuevas formulaciones de vacuna contra el papiloma virus humano (HPV) presentan una acrecentada estabilidad a largo plazo. Los componentes de laformulacion pueden incluir: partículas similares a virus (VLPs) absorbidas sobre aluminio, una sal, unsurfactante no ionico, y un tampon. Las formulacionesadicionales también contienen un estabilizante polimérico polianionico y una sal, sea en la presencia sea en la ausencia de agentes tamponantes y de detergenteno-ionico.
ARP000100495A 1999-02-05 2000-02-04 Formulaciones de vacunas contra el papilomavirus humano AR022510A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11872399P 1999-02-05 1999-02-05

Publications (1)

Publication Number Publication Date
AR022510A1 true AR022510A1 (es) 2002-09-04

Family

ID=22380362

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100495A AR022510A1 (es) 1999-02-05 2000-02-04 Formulaciones de vacunas contra el papilomavirus humano

Country Status (15)

Country Link
US (1) US6251678B1 (es)
EP (1) EP1150712B1 (es)
JP (2) JP4841726B2 (es)
KR (1) KR20010093290A (es)
AR (1) AR022510A1 (es)
AT (1) ATE413188T1 (es)
AU (1) AU764138B2 (es)
CA (1) CA2361837C (es)
CY (1) CY1108702T1 (es)
DE (1) DE60040727D1 (es)
DK (1) DK1150712T3 (es)
ES (1) ES2313881T3 (es)
PT (1) PT1150712E (es)
SI (1) SI1150712T1 (es)
WO (1) WO2000045841A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA982950B (en) * 1997-04-08 1998-10-19 Merck & Co Inc Stabilized human papillomavirus formulations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
WO2002013860A1 (fr) * 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
CA2327950A1 (en) * 2000-12-08 2002-06-08 Groupe Minutia Inc. Grain refining agent for cast aluminum or magnesium products
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
PL371261A1 (en) * 2002-01-18 2005-06-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
AU2003219760A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AP2005003347A0 (en) * 2002-12-20 2005-06-30 Glayosmithkline Biolog S A HPV-16 and-18 Lu VLP vaccine
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
JP2007001865A (ja) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
US7608278B2 (en) 2003-12-30 2009-10-27 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
CA2588274A1 (en) * 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
MX2007003954A (es) * 2004-10-05 2007-06-14 Cytos Biotechnology Ag Conjugados de antigeno de particula tipo virus y su uso como vacunas.
JP4182074B2 (ja) * 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
CA2600036A1 (en) * 2005-03-04 2006-09-14 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
DK2066354T3 (da) 2006-09-29 2013-05-27 Ligocyte Pharmaceuticals Inc Norovirus vaccine formuleringer
ES2673823T3 (es) * 2006-11-03 2018-06-25 Alphavax, Inc. Formulaciones de alfavirus y de partículas de replicones de alfavirus y métodos relacionados
EP2129394B1 (en) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP2010539192A (ja) 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド ノロウイルスに対して防御免疫応答を付与する方法
EP2258380B1 (en) 2008-03-31 2013-03-13 Morinaga Milk Industry Co., Ltd. Nucleic acid for imparting heat resistance to lactoferrin
WO2011079260A2 (en) * 2009-12-23 2011-06-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
HRP20210242T4 (hr) 2010-08-23 2024-05-10 Wyeth Llc Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
US20130259948A1 (en) 2010-09-21 2013-10-03 National Institute Of Immunology Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
RU2610174C2 (ru) * 2011-06-24 2017-02-08 Мерк Шарп И Доум Корп. Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения
JP6208659B2 (ja) 2011-07-11 2017-10-04 タケダ ワクチン，インコーポレイテッド 非経口ノロウイルスワクチン製剤
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
EP2802649B1 (en) 2012-01-09 2017-08-09 Sanofi Pasteur Biologics, LLC Purification of herpes virus
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2013177172A2 (en) * 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
CN104379170B (zh) 2012-06-20 2017-05-03 国立大学法人东京大学 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物
WO2014100860A2 (en) * 2012-12-28 2014-07-03 Cellestis Limited A cell mediated immune response assay
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
US9254332B2 (en) * 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3100049B1 (en) 2014-01-31 2019-11-06 Ulisse Biomed S.R.L. Biosensors for the detection of infection and associated maladies
CN104479892A (zh) * 2014-11-06 2015-04-01 王越 一种具有植物杀菌功能洗衣液的制备方法
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3019515A1 (en) 2016-04-01 2017-10-05 Colorado State University Research Foundation Compositions and methods for enhanced innate immunity
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3079828A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
WO2024111566A1 (ja) * 2022-11-22 2024-05-30 一般財団法人阪大微生物病研究会 安定化されたｖｌｐワクチン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
PL183781B1 (pl) * 1994-05-16 2002-07-31 Merck & Co Inc Sposób wytwarzania szczepionki przeciwko ludzkiemu wirusowi brodawczaków
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
EP0939648B1 (en) * 1996-09-26 2007-11-07 Merck & Co., Inc. Rotavirus vaccine formulations
ATE470434T1 (de) * 1997-02-06 2010-06-15 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
KR20010006169A (ko) * 1997-04-08 2001-01-26 폴락 돈나 엘. 안정화된 사람 파필로마바이러스 제형물

Also Published As

Publication number Publication date
US6251678B1 (en) 2001-06-26
DE60040727D1 (de) 2008-12-18
ES2313881T3 (es) 2009-03-16
AU764138B2 (en) 2003-08-14
JP4841726B2 (ja) 2011-12-21
CA2361837C (en) 2011-06-07
JP2002536340A (ja) 2002-10-29
DK1150712T3 (da) 2009-02-02
AU2749200A (en) 2000-08-25
JP2011225578A (ja) 2011-11-10
CA2361837A1 (en) 2000-08-10
ATE413188T1 (de) 2008-11-15
PT1150712E (pt) 2008-12-22
WO2000045841A2 (en) 2000-08-10
EP1150712A2 (en) 2001-11-07
CY1108702T1 (el) 2013-09-04
EP1150712B1 (en) 2008-11-05
KR20010093290A (ko) 2001-10-27
WO2000045841A3 (en) 2000-12-14
SI1150712T1 (sl) 2009-02-28

Similar Documents

Publication Publication Date Title
AR022510A1 (es) Formulaciones de vacunas contra el papilomavirus humano
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
BR0112071A (pt) Vacina contra a febre aftosa
CY1107457T1 (el) Εμβoλιο κατa του hpv
PE20020968A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada
DK0853660T3 (da) Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
ECSP045300A (es) Antígenos virales
ES2083764T3 (es) Vacuna contra el sindrome respiratorio reproductivo porcino (srrp) y diagnostico.
AR039688A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
WO2001068129A3 (de) Adjuvans für vakzinen
CA2331368A1 (en) Nucleic acid vaccines for prevention of flavivirus infection
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
NO994879L (no) Stabiliserte humane papillomvirusformuleringer
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
AR026637A1 (es) Virus atenuados e inocuos de la diarrea virica bovina para uso en vacas gestantes
AR031679A1 (es) Una composicion farmaceutica
BR9809708A (pt) Composições farmacêuticas de peptìdeos tendo solubilidade baixa em meio fisiológico
AR040623A1 (es) Vacuna contra el virus de la aftosa.
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
AP2001002254A0 (en) Treatment of chronic viral infections with M. Vaccae.
AU4078401A (en) Viral antigen and vaccine against isav (infectious salmon anaemia virus)
RS20120367A2 (en) METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C
EA199900915A1 (ru) Стабилизированные композиции вируса папилломы человека